What is the highest and lowest stock price for Bristol Myers Squibb?
Bristol-Myers Squibb Co (BMY) Stock Price & News - Google Finance. BMY • NYSE. Bristol-Myers Squibb Co. $76.15. Pre-market: $76.01. (0.18%) -0.14. Closed: May …
What does the company Bristol Myers Squibb do?
May 12, 2022 · The low in the last 52 weeks of Bristol-Myers Squibb stock was 53.22. According to the current price, Bristol-Myers Squibb is 143.37% away from the 52-week low.
Who bought BMY stock in the last quarter?
Find historical stock quotes and get information including opening price, stock performance and more. ... -looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb's business, particularly those identified in the cautionary factors discussion in the company’s most ...
When is the Bristol-Myers Squibb earnings conference call?
View the latest Bristol Myers Squibb Co. (BMY) stock price, news, historical charts, analyst ratings and financial information from WSJ.
At what price did Bristol Myers close on the market?
...
Bristol Myers Squibb Co.
| Volume | 15.65M |
|---|---|
| Market Value | $162.94B |
| Shares Outstanding | 2.18B |
| EPS (TTM) | $2.82 |
| P/E Ratio (TTM) | 27.21 |
Is Bristol Myers a US company?
When did Bristol Myers stock split?
| Record Date | Description |
|---|---|
| May 20, 1974 | Stock split |
| January 2, 1987 | Westmark International spin off from Squibb Corp. |
| June 1, 1987 | Stock split |
| October 4, 1989 | Squibb Corporation and Bristol-Myers Company merged to form Bristol-Myers Squibb Company |
Why is BMY stock down?
Is Bristol-Myers Squibb a good stock to buy?
When did Bristol Myers go public?
How many stock splits has Tesla had?
What was Tesla stock split?
How many stock splits has Amazon done?
Amazon is no stranger to stock splits. It's carried out three in its history. But they haven't been in the company's most recent history. They all happened in the period of 1998 through 1999.Mar 14, 2022
Does Bristol Myers pay a dividend?
Is Bristol-Myers Squibb a BUY SELL HOLD?
What did Bristol Myers close at?
| Previous Close | 76.25 |
|---|---|
| Bid | 76.61 x 1800 |
| Ask | 76.62 x 1800 |
| Day's Range | 75.76 - 76.85 |
| 52 Week Range | 53.22 - 78.17 |
Where is BMS headquartered?
What is the BMS?
Reported on 4/28/21. Bristol Myers Squibb is an American multinational pharmaceutical company, headquartered in New York City . BMS is one of the world's largest pharmaceutical companies, and is consistently ranked on the Fortune 500 list of the largest U.S. corporations. As of September 2020, it had the total revenue of $39.3 billion.
What is BMS pharmaceutical?
Bristol Myers Squibb is an American multinational pharmaceutical company, headquartered in New York City. BMS is one of the world's largest pharmaceutical companies, and is consistently ranked on the Fortune 500 list of the largest U.S. corporations. As of September 2020, it had the total revenue of $39.3 billion.
Where is BMS located?
About. . Bristol Myers Squibb is an American multinational pharmaceutical company , headquartered in New York City. BMS is one of the world's largest pharmaceutical companies, and is consistently ranked on the Fortune 500 list of the largest U.S. corporations. As of September 2020, it had the total revenue of $39.3 billion.
What is the consensus rating for Bristol Myers Squibb?
Bristol Myers Squibb is an American multinational pharmaceutical company, headquartered in New York City . BMS is one of the world's largest pharmaceutical companies, and is consistently ranked on the Fortune 500 list of the largest U.S. corporations.
What is the company that makes Revlimid?
Bristol-Myers Squibb has received a consensus rating of Buy. The company's average rating score is 2.86, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.
Stock Chart
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; and DarwinHealth, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Stock Quote Historical
Zoom From Jun 1, 2021 To Aug 30, 2021 NYSE:BMY News 7. Jun 14. Jun 21. Jun 28. Jun 5. Jul 12. Jul 19. Jul 26. Jul 2. Aug 9. Aug 16. Aug 23. Aug 30. Aug 2016 2017 2018 2019 2020 2021 65 70 62.5 67.5 1m 3m 6m YTD 1y All Q4 Web Systems
Email Alerts
Quotes delayed at least 20 minutes. Market data provided by Ticker Tech.
What is the focus of Bristol Myers Squibb?
Click investor alerts to manage event, presentation and SEC Filing email notifications, or select press release alerts to subscribe to company news alerts.
What is Bristol's focus?
A key focus for Bristol is immuno-oncology, where the firm is leading in drug development.
Is Bristol Myers Squibb a sponsor?
A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. Key Executives.
What is book entry form?
The program is not sponsored or administered by Bristol Myers Squibb. For additional information, please contact our transfer agent, EQ Shareowner Services, at 855-598-5485. Or you may access your account and enroll online at www.shareowneronline.com.
Ownership
- Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol \"BMY.\" Bristol-Myers Squibb saw a increase in short interest in April. As of April 15th, there was short interest totalling 77,458,472 shares, an increase of 61.2% from the March 29th total of 48,063,938 shares. Based on an average daily volume of 18,421,723 shares, the short-interest ra…
Results
- Bristol-Myers Squibb Co (NYSE:BMY) posted its earnings results on Thursday, April, 25th. The biopharmaceutical company reported $1.10 EPS for the quarter, beating the consensus estimate of $1.09 by $0.01. The biopharmaceutical company earned $5.92 billion during the quarter, compared to analysts' expectations of $5.72 billion. Bristol-Myers Squibb had a return on equity …
Release
- Bristol-Myers Squibb is scheduled to release their next quarterly earnings announcement on Thursday, July 25th 2019. View Earnings Estimates for Bristol-Myers Squibb.
Sales
- Bristol-Myers Squibb updated its FY19 earnings guidance on Thursday, April, 25th. The company provided earnings per share guidance of $4.10-4.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.18. Bristol-Myers Squibb also updated its FY 2019 guidance to $4.10-4.20 EPS.
Ratings
- 16 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Bristol-Myers Squibb in the last year. There are currently 9 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of \"Hold.\" View Analyst Ratings for Bristol-Myers Squibb.
Reception
- Press coverage about BMY stock has been trending somewhat positive this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Bristol-Myers Squibb earned a new…
Business
- Bristol-Myers Squibb has a market capitalization of $76.89 billion and generates $22.56 billion in revenue each year. The biopharmaceutical company earns $4.92 billion in net income (profit) each year or $3.98 on an earnings per share basis. Bristol-Myers Squibb employs 23,300 workers across the globe.
Location
- Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected].